Design Therapeutics (DSGN) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Janux Therapeutics (JANX) over the past year, gaining 8.0% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -49.3% for DSGN. Janux Therapeutics is the larger company by market cap ($616.7 million vs $577.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | JANX |
|---|---|---|
| Share price | $9.02 | $10.08 |
| Market cap | $577.61M | $616.73M |
| 1-day change | -3.22% | -2.04% |
| YTD return | -3.84% | -26.96% |
| 1-year return | +8.02% | -65.00% |
| 5-year return | -49.27% | -42.92% |
| EPS (TTM) | $-1.20 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $10.00M |
| Revenue growth (YoY) | — | -5.55% |
| Net income (latest FY) | $-69.79M | $-113.63M |
| Operating margin | — | -1576.67% |
| Net margin | — | -1136.25% |
| 52-week high | $17.25 | $35.34 |
| 52-week low | $8.21 | $10.05 |
| Distance from 52-week high | -47.71% | -71.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +139.14% | +228.77% |
| Average volume | 554.69K | 961.56K |
| Shares outstanding | 64.04M | 61.18M |
| Employees | 60 | 114 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed JANX by 73.0 percentage points over the past year.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
DSGN vs JANX FAQ
Which is bigger, Design Therapeutics or Janux Therapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $577.61M for Design Therapeutics (DSGN).
Which stock has performed better over the past year, DSGN or JANX?
DSGN returned +8.02% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Design Therapeutics and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.